Kolistin Zentiva (Colistimethate Sodium)

Colistimethate sodium binds to the lipopolysaccharide and phospholipid components of the outer membrane of Gram‑negative bacteria, disrupting membrane integrity. This leads to increased permeability, leakage of cellular contents, and ultimately bacterial cell death.

The dosage of Kolistin Zentiva is determined by the prescribing clinician based on the infection type, severity, patient renal function, and route of administration. Dosage regimens are individualized and should follow local clinical guidelines.

Safety data for colistimethate sodium in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Kolistin Zentiva, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Kolistin Zentiva (colistimethate sodium) is a pro‑drug that is converted to colistin in the body, offering similar antibacterial activity to other Polymyxins such as polymyxin B. Differences may include dosing schedules, pharmacokinetic profiles, and specific regulatory approvals, but all share the same mechanism of disrupting Gram‑negative bacterial membranes.

Kolistin Zentiva should be stored below 25 °C in its original packaging, protected from moisture and light. For inhalation solutions, avoid freezing and keep the vial sealed until use. Follow any additional handling instructions provided with the product.

Kolistin Zentiva is available for inhalation and intravenous administration. The inhalation form is delivered via a nebulizer to the lungs, while the intravenous form is given as an infusion under clinical supervision, with dosing adjusted according to patient-specific factors.

The most serious risks include nephrotoxicity, which can lead to acute kidney injury, and neurotoxicity, which may manifest as seizures or severe peripheral neuropathy. Prompt monitoring of renal function and neurological status is essential during therapy.

Kolistin Zentiva is contraindicated in patients with known hypersensitivity to colistimethate sodium or any component of the formulation. Caution is also advised for individuals with pre‑existing severe renal impairment, neuromuscular disorders, or those receiving other nephrotoxic or neurotoxic agents.